Clinical trials: Decompensated Heart Failure
Decompensated Heart Failure
Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure
This study is designed to investigate the quantitative effects of sodium-free chloride supplementation on electrolyte balance, volume status, and sodium avidity in stable heart failure patients in a highly controlled environment.
- Trial name
- NCT03440970
- Testing
- Lysine Chloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Yale University
Acute Decompensated Heart Failure
The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure
To assess the safety, tolerability and efficacy of two different doses of istaroxime, a new agent with lusitropic and inotropic activities that improves the cardiac contraction-relaxation cycle.
- Trial name
- NCT02617446
- Testing
- Istaroxime
- Where
- 11 sites in China, Italy
- Volunteers
- 120 people
- Sponsor
- Windtree Therapeutics
Acute Decompensated Heart Failure
Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS)
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure…
- Trial name
- FASTR (NCT05174312)
- Testing
- Reprieve Decongestion Management System, Diuretic
- Where
- 16 sites in United States
- Volunteers
- 100 people
- Sponsor
- Reprieve Cardiovascular, Inc
Heart Failure
Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)
Heart failure is a serious condition in which the heart's ability to pump blood through the body is impaired, often making a person feel weak or fatigued.
- Trial name
- CARRESS (NCT00608491)
- Testing
- Stepped pharmacologic care, Ultrafiltration
- Where
- 9 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- Duke University
Acute Heart Failure, Decompensated Heart Failure
Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study
To determine if a strategy of early discharge using a novel subcutaneous delivery system for parenteral furosemide can improve clinical outcomes within 30 days of randomization (days alive and outside the hospital) compared to…
- Trial name
- SUBQ-HF (NCT03170219)
- Testing
- subcutaneous furosemide and sc2wear device
- Where
- 16 sites in United States
- Volunteers
- 11 people
- Sponsor
- Adrian Hernandez
Heart Failure
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level.
- Trial name
- ESCAPE-SHF (NCT00923156)
- Testing
- aliskiren, ramipril
- Where
- 16 sites in Germany, Poland and 1 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Acute Decompensated Heart Failure
Assessment of Coronary Flow Reserve in Heart Failure Patients After Ultrafiltration Versus Diuretics
The purpose of this research study is to compare the effects (good and bad) of ultrafiltration treatment with standard intravenous (in your vein) diuretic therapy (furosemide, torsemide, bumetanide) on your heart function and…
- Trial name
- NCT01457053
- Testing
- Loop diuretics (furosemide, torsemide, bumetanide), Ultrafiltration
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- University of Cincinnati
Heart Failure, Congestive
A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure
Transient receptor potential vanilloid 4 (TRPV4) channel blockade may be promising in the treatment of pulmonary oedema and dyspnoea in heart failure (HF) and acute decompensated heart failure (ADHF) patients by re-establishing…
- Trial name
- NCT02135861
- Testing
- DCE-MRI scans, Gadobutrol
- Where
- United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Decompensated Heart Failure
Assessment of Biomarkers and Cardiorenal Syndrome in Acute Decompensated Heart Failure With Vasodilator Therapy
The purpose of this study is to determine whether Nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.
- Trial name
- ABC-HFT (NCT00842023)
- Testing
- Nesiritide, Nitroglycerin
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Western University of Health Sciences
Heart Failure Acute, Heart Failure，Congestive
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide.
- Conditions
- Heart Failure Acute, Heart Failure，Congestive, Heart Failure; With Decompensation
- Trial name
- EMPA-RESPONSE (NCT03200860)
- Testing
- Empagliflozin 10 MG
- Where
- 5 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- University Medical Center Groningen
Heart Failure, Sleep Apnea Syndromes
Treatment of Sleep Disordered Breathing In Acute Decompensated Heart Failure Patients
Heart Failure affects 5-6 million Americans and there are about 550 thousand new cases of heart failure every year. There are approximately 3 million hospital admission for acute decompensated heart failure with hospital…
- Trial name
- ARIA-II (NCT00804349)
- Testing
- Autotitrating Positive Airway Pressure
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Albert Einstein Healthcare Network
Heart Failure, Myocardial Infarction
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a…
- Trial name
- INVESTED (NCT02787044)
- Testing
- High Dose Trivalent Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine
- Where
- 190 sites in United States, Canada and 1 more
- Volunteers
- 5,388 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure, Diabetes
Thiamine and Acute Decompensated Heart Failure: Pilot Study
Heart failure remains an increasing cause of morbidity and mortality in the United States even in the face of recent advances in the treatment of cardiovascular disease.
- Trial name
- NCT00680706
- Testing
- Thiamine
- Where
- 2 sites in United States
- Volunteers
- 131 people
- Sponsor
- Baystate Medical Center
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure
Broad Objectives: To determine the comparative efficacy of commonly employed strategies to overcome loop diuretic resistance when added to concomitant loop diuretics in hospitalized decompensated heart failure patients with…
- Trial name
- NCT02606253
- Testing
- tolvaptan, Chlorothiazide, Metolazone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University
Heart Failure, Systolic, Inflammation
Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2
REDHART2 is a randomized, double-blinded, placebo-controlled trial to determine the effects of Anakinra on peak aerobic exercise capacity measured with a cardiopulmonary test after 24 weeks in patients with recently decompensated…
- Trial name
- REDHART2 (NCT03797001)
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Virginia Commonwealth University
CHF
FAST PV and mGFR™ Technology in Congestive Heart Failure
This is an investigator-initiated, one-armed, phase 2 clinical trial using an injectable fluorescent tracer to assay and evaluate measured plasma volume (mPV) and measured glomerular filtration rate (mGFR) in hospitalized…
- Trial name
- NCT03808948
- Testing
- VFI
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Charite University, Berlin, Germany
Acute Decompensated Heart Failure, Acute Kidney Injury
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
AKINESIS is a clinical study to assess the utility of blood and urine NGAL tests in predicting worsening kidney function in patients who present with acute heart failure (AHF) and who are treated with diuretics.
- Trial name
- AKINESIS (NCT01291836)
- Where
- 13 sites in United States, Greece and 5 more
- Volunteers
- 930 people
- Sponsor
- Alere San Diego
Heart Decompensation
A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure
The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties…
- Trial name
- NCT00475852
- Testing
- Nesiritide
- Where
- 328 sites in United States, Argentina and 26 more
- Volunteers
- 7,141 people
- Sponsor
- Scios, Inc.
Heart Failure, Cardiac Failure
Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment
The purpose of the research is to determine if patients have fewer Heart Failure (HF) events after receiving Aquapheresis (AQ) therapy compared to intravenous (IV) diuretics up to 90 days of discharge from the hospital.
- Conditions
- Heart Failure, Cardiac Failure, Acute Decompensated Heart Failure (ADHF)
- Trial name
- AVOID-HF (NCT01474200)
- Testing
- Isolated veno-venous ultrafiltration (AQ), IV Loop Diuretics (LD)
- Where
- 38 sites in United States
- Volunteers
- 224 people
- Sponsor
- Nuwellis, Inc.